Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1956 1
1959 1
1962 1
1965 2
1966 1
1968 4
1969 1
1970 1
1971 4
1972 5
1973 1
1974 5
1975 4
1977 1
1978 3
1979 1
1980 3
1981 1
1982 1
1986 3
1987 2
1988 5
1989 3
1990 4
1991 2
1992 2
1993 5
1994 3
1995 5
1996 6
1997 2
1998 1
2007 2
2008 1
2010 5
2011 3
2012 2
2013 2
2014 2
2015 3
2016 3
2017 2
2018 5
2019 3
2020 4
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
ISO/TS 20914:2019 - a critical commentary.
Farrance I, Frenkel R, Badrick T. Farrance I, et al. Among authors: frenkel r. Clin Chem Lab Med. 2020 Jul 28;58(8):1182-1190. doi: 10.1515/cclm-2019-1209. Clin Chem Lab Med. 2020. PMID: 32238602 Review.
Measurement uncertainty and the importance of correlation.
Farrance I, Frenkel R. Farrance I, et al. Among authors: frenkel r. Clin Chem Lab Med. 2020 Sep 2;59(1):7-9. doi: 10.1515/cclm-2020-1205. Clin Chem Lab Med. 2020. PMID: 32877359 Free article. No abstract available.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Use of colour Doppler imaging in ocular blood flow research.
Stalmans I, Vandewalle E, Anderson DR, Costa VP, Frenkel RE, Garhofer G, Grunwald J, Gugleta K, Harris A, Hudson C, Januleviciene I, Kagemann L, Kergoat H, Lovasik JV, Lanzl I, Martinez A, Nguyen QD, Plange N, Reitsamer HA, Sehi M, Siesky B, Zeitz O, Orgül S, Schmetterer L. Stalmans I, et al. Among authors: frenkel re. Acta Ophthalmol. 2011 Dec;89(8):e609-30. doi: 10.1111/j.1755-3768.2011.02178.x. Epub 2011 Oct 11. Acta Ophthalmol. 2011. PMID: 21989301 Free article. Review.
132 results